Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. Cancer J Clin. 2014;64(1):9–29.

Article  Google Scholar 

Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lehtio J, De Petris L. Lung cancer proteomics, clinical and technological considerations. J Proteom. 2010;73(10):1851–63.

Article  Google Scholar 

Cheng S, Evans WK, Stys-Norman D, Shepherd FA, Lung Cancer Disease Site Group of Cancer Care. Ontario’s program in evidence-based C. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2007;2(4):348–54.

Article  Google Scholar 

Hurwitz JL, McCoy F, Scullin P, Fennell DA. New advances in the second-line treatment of small cell lung cancer. Oncologist. 2009;14(10):986–94.

Article  CAS  PubMed  Google Scholar 

Rodriguez E, Lilenbaum RC. Small cell lung cancer: past, present, and future. Curr Oncol Rep. 2010;12(5):327–34.

Article  PubMed  Google Scholar 

Fischer B, Arcaro A. Current status of clinical trials for small cell lung cancer. Rev Recen Clin Trial. 2008;3(1):40–61.

Article  CAS  Google Scholar 

Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst. 2007;99(11):838–46.

Article  CAS  PubMed  Google Scholar 

Wu X, Liang W, Hou X, Lin Z, Zhao H, Huang Y, Fang W, Zhao Y, Wu J, Yang Y, Xue C, Hu Z, Zhang J, et al. Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC. OncoTargets Therapy. 2013;6:1481–91.

CAS  PubMed  PubMed Central  Google Scholar 

Miescher Schwenninger S, Freimuller Leischtfeld S, Gantenbein-Demarchi C. High-throughput identification of the microbial biodiversity of cocoa bean fermentation by MALDI-TOF MS. Letters in applied microbiology. 2016.

Takashima M, Kuramitsu Y, Yokoyama Y, Iizuka N, Harada T, Fujimoto M, Sakaida I, Okita K, Oka M, Nakamura K. Proteomic analysis of autoantibodies in patients with hepatocellular carcinoma. Proteomics. 2006;6(13):3894–900.

Article  CAS  PubMed  Google Scholar 

Engwegen JY, Helgason HH, Cats A, Harris N, Bonfrer JM, Schellens JH, Beijnen JH. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol. 2006;12(10):1536–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gamez-Pozo A, Sanchez-Navarro I, Nistal M, Calvo E, Madero R, Diaz E, Camafeita E, de Castro J, Lopez JA, Gonzalez-Baron M, Espinosa E, Fresno Vara JA. MALDI profiling of human lung cancer subtypes. PLoS ONE. 2009;4(11):e7731.

Article  PubMed  PubMed Central  Google Scholar 

Monari E, Casali C, Cuoghi A, Nesci J, Bellei E, Bergamini S, Fantoni LI, Natali P, Morandi U, Tomasi A. Enriched sera protein profiling for detection of non-small cell lung cancer biomarkers. Proteome Sci. 2011;9(1):55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

He P, Naka T, Serada S, Fujimoto M, Tanaka T, Hashimoto S, Shima Y, Yamadori T, Suzuki H, Hirashima T, Matsui K, Shiono H, Okumura M, Nishida T, Tachibana I, Norioka N, et al. Proteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer. Cancer Sci. 2007;98(8):1234–40.

Article  CAS  PubMed  Google Scholar 

Chen G, Gharib TG, Huang CC, Thomas DG, Shedden KA, Taylor JM, Kardia SL, Misek DE, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, Beer DG. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin cancer Research: Official J Am Association Cancer Res. 2002;8(7):2298–305.

CAS  Google Scholar 

Chatterji B, Borlak J. Serum proteomics of lung adenocarcinomas induced by targeted overexpression of c-raf in alveolar epithelium identifies candidate biomarkers. Proteomics. 2007;7(21):3980–91.

Article  CAS  PubMed  Google Scholar 

Glisson BS. Recurrent small cell lung cancer: update. Semin Oncol. 2003;30(1):72–8.

Article  PubMed  Google Scholar 

van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011;378(9804):1741–55.

Article  PubMed  Google Scholar 

Roberti A, La Sala D, Cinti C. Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. J Cell Physiol. 2006;207(3):571–81.

Article  CAS  PubMed  Google Scholar 

Stoeckli M, Chaurand P, Hallahan DE, Caprioli RM. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med. 2001;7(4):493–6.

Article  CAS  PubMed  Google Scholar 

Pusch W, Kostrzewa M. Application of MALDI-TOF mass spectrometry in screening and diagnostic research. Curr Pharm Design. 2005;11(20):2577–91.

Article  CAS  Google Scholar 

Musharraf SG, Hashmi N, Choudhary MI, Rizvi N, Usman A, Atta ur R. Comparison of plasma from healthy nonsmokers, smokers, and lung cancer patients: pattern-based differentiation profiling of low molecular weight proteins and peptides by magnetic bead technology with MALDI-TOF MS. biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals. 2012;17(3):223–30.

Voortman J, Pham TV, Knol JC, Giaccone G, Jimenez CR. Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling. Proteome Sci. 2009;7:34.

Article  PubMed  PubMed Central  Google Scholar 

Rovithi M, Lind JS, Pham TV, Voortman J, Knol JC, Verheul HM, Smit EF, Jimenez CR. Response and toxicity prediction by MALDI-TOF-MS serum peptide profiling in patients with non-small cell lung cancer. Proteom Clin Appl. 2016;10(7):743–9.

Article  CAS  Google Scholar 

Yanagisawa K, Tomida S, Shimada Y, Yatabe Y, Mitsudomi T, Takahashi T. A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. J Natl Cancer Inst. 2007;99(11):858–67.

Article  CAS  PubMed  Google Scholar 

Yang L, Tang C, Xu B, Wang W, Li J, Li X, Qin H, Gao H, He K, Song S, Liu X. Classification of epidermal growth factor receptor gene mutation status using serum proteomic profiling predicts tumor response in patients with stage IIIB or IV non-small-cell lung cancer. PLoS ONE. 2015;10(6):e0128970.

Article  PubMed  PubMed Central  Google Scholar 

Han M, Dai J, Zhang Y, Lin Q, Jiang M, Xu X, Liu Q, Jia J. Support vector machines coupled with proteomics approaches for detecting biomarkers predicting chemotherapy resistance in small cell lung cancer. Oncol Rep. 2012;28(6):2233–8.

Article  CAS  PubMed  Google Scholar 

Cricca M, Marasco E, Alessandrini F, Fazio C, Prossomariti A, Savini C, Venturoli S, Chieco P, De Carolis S, Bonafe M, Re MC, Garagnani P, Mantovani V. High-throughput genotyping of high-risk human papillomavirus by MALDI-TOF Mass Spectrometry-based method. new Microbiol. 2015;38(2):211–23.

CAS  PubMed  Google Scholar 

Milan E, Lazzari C, Anand S, Floriani I, Torri V, Sorlini C, Gregorc V, Bachi A. SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors. J Proteom. 2012;76 Spec No.:91–101.

Dekker LJ, Boogerd W, Stockhammer G, Dalebout JC, Siccama I, Zheng P, Bonfrer JM, Verschuuren JJ, Jenster G, Verbeek MM, Luider TM, Smitt PA. MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer. Mol Cell Proteomics: MCP. 2005;4(9):1341–9.

Article  CAS  PubMed  Google Scholar 

Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Investig. 2006;116(1):271–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Milioli HH, Santos Sousa K, Kaviski R, Dos Santos Oliveira NC, De Andrade Urban C, De Lima RS, Cavalli IJ, De Souza Fonseca Ribeiro EM. Comparative proteomics of primary breast carcinomas and lymph node metastases outlining markers of tumor invasion. Cancer Genomics Proteomics. 2015;12(2):89–101.

CAS  PubMed  Google Scholar 

Boccardo F, Rubagotti A, Nuzzo PV, Argellati F, Savarino G, Romano P, Damonte G, Rocco M, Profumo A. Matrix-assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery. Int J Cancer. 2015;137(10):2394–402.

Article  CAS  PubMed  Google Scholar 

Kumarathasan P, Mohottalage S, Goegan P, Vincent R. An optimized protein in-gel digest method for reliable proteome characterization by MALDI-TOF-MS analysis. Anal Biochem. 2005;346(1):85–9.

Article  CAS  PubMed  Google Scholar 

Bruenner BA, Yip TT, Hutchens TW. Quantitative analysis of oligonucleotides by matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun mass Spectrometry: RCM. 1996;10(14):1797–801.

Article  CAS  PubMed  Google Scholar 

Petricoin EF, Belluco C, Araujo RP, Liotta LA. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer. 2006;6(12):961–7.

Article  CAS  PubMed  Google Scholar 

De Bock M, de Seny D, Meuwis MA, Chapelle JP, Louis E, Malaise M, Merville MP, Fillet M. Challenges for biomarker discovery in body fluids using SELDI-TOF-MS. J Biomed Biotechnol. 2010;2010:906082.